The KRAS selectivity of the drug conjugate using dextran with the right size was then assessed, and any favorable in vivo effects, in particular, relief of the tumor immune microenvironment, were studied using multiple complementary pancreatic tumor mouse models. Here, KRAS is linked to pancreatic neoplasm.